A venture capital firm founded in 2024 and has USD $40M under management seeks to invest in Pre-Seed and Seed stage longevity biotech companies developing technologies that can significantly extend healthy human lifespan and are scalable for everyone. Initial check size ranges between USD $250K – $1.5M with the ability to lead or co-lead. The firm is open to global companies but prefers the US, UK, and EU.
The firm is open to all technologies, except single assets, that address longevity. Areas of interest include breakthroughs in multiple areas including AI, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, tissue engineering, and more. Every company they invest in must have the potential to extend healthy human lifespan by at least 10+ years. Companies of interest are typically still in pre-clinical stages. The firm seeks out companies with a strong ethical foundation and robust scientific backing.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.





Leave a comment